Research Article

Case Report of RANBP2 Mutation and Familial Acute Necrotizing Encephalopathy

Mohamad Paktinat,1 Kamran Hessami,2,3 Soroor Inaloo,1 Hamid Nemati,1 Pegah Katibeh,1 Marzieh Nejabat,1 Mohammad Hassan Darabi,2 and Ali Hosseini Bereshneh1

1Neonatology Research Center, Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
3Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
4Prenatal Diagnosis and Genetic Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence should be addressed to Kamran Hessami; hessamikamran@gmail.com

Received 22 December 2020; Revised 18 February 2021; Accepted 27 February 2021; Published 13 March 2021

Academic Editor: Alessandro Mussa

Copyright © 2021 Mohamad Paktinat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Acute necrotizing encephalopathy (ANE) is a rare disorder typically associated with early onset seizures, focal neurological deficits, and rapid deterioration of consciousness, which may ultimately progress to coma [1]. There is an association between ANE and previous upper respiratory infection with organisms like influenza A or parainfluenza, but direct involvement of central nervous system by these agents is unlikely [1].

Findings of neuroradiological studies such as multiple symmetrical lesions involving thalami, brainstem, cerebral white matter, cerebellum, and less frequently spinal cord can assist physicians for the early diagnosis of ANE [2]. The exact pathophysiology of ANE remains to be understood; however, recent studies have suggested that both environmental and genetic factors may play a role in developing ANE [3]. Recently, a number of familial cases of ANE have been identified, all of them showing mutations in RANBP2 gene [4–8].

Considering the rarity of ANE as well as lack of sufficient data on familial cases, we gathered data on three cases of familial ANE in Iran associated with RANBP2 gene mutation.

2. Case Presentation

2.1. Case 1. A 9-year-old girl presented with a decreased level of consciousness, fever, and generalized tonic-colonic seizure with no history of recent traumatic brain injury. Physical examination was unremarkable. The patient had experienced common cold symptoms which resolved two days prior to admission.
neurological deficit. Laboratory findings and cerebrospinal fluid (CSF) analysis were within normal ranges. The patient had a similar presentation about 2 years prior to current admission. At the previous presentation 2 years ago, brain magnetic resonance imaging (MRI) revealed hyperintensity of external capsule, cerebellar peduncle, andpons (Figure 1(a)); therefore, she was admitted in pediatric intensive care unit (PICU) for 5 days and received methylprednisolone (2 mg/kg/day) and intravenous immunoglobulin (IVIG) (2 g/kg/day), as a potential case of ANE. Finally, she was discharged with a mild dysarthria considered as neurologic sequelae of ANE. At the current presentation, she was admitted in PICU for 25 days and again received IVIG (2 g/kg/day) and methyl prednisolone (2 mg/kg/day). Brain MRI showed extensive involvement of both basal ganglia, external capsules, both mesial temporal areas, brainstem, and both sides of cerebellar hemisphere (Figure 1(b)). Electroencephalogram (EEG) revealed low-voltage slow wave pattern, suggestive of nonepileptic encephalopathy. Eventually, she was discharged after 1 month with normal cognitive function and her speech ability was relatively recovered with a short period of rehabilitation.

2.2. Case 2. A 4-year-old boy, the brother of the aforementioned case, presented with fever, decreased level of consciousness, and generalized tonic-colonic seizure. Initial examination revealed drowsiness without any focal neurologic deficit. There was no history of recent traumatic brain injury. Family history was positive for ANE in his sister. Laboratory findings were well within normal ranges. CSF analysis did not show pleocytosis, although elevated protein levels were detected. Brain MRI showed increased signal intensity in both thalami, external capsules, midbrain andpons, and also the cortex of the cerebellum (Figure 2(a)). IVIG (2 g/kg/day), methyl prednisolone (2 mg/kg/day), and rituximab (375 mg/m², single dose) were administered, respectively. After a 15-day period of PICU admission, the patient was discharged with no neurologic sequelae. Genetic analysis showed that both siblings (cases 1 and 2) were heterozygous for RANBP2 mutation (c.C1754T: p.T585M). Further genetic investigation revealed the same mutation in their mother, but she had no history of similar symptoms.

2.3. Case 3. A 6-year-old boy, the maternal cousin of previous cases, was brought to the emergency room due to generalized tonic-colonic seizure, drowsiness, and fever. Two years earlier, the patient had the similar presentations and was admitted to the pediatric neurology ward with the impression of meningitis and received empirical antibiotic therapy with vancomycin (60 mg/kg/day) and ceftriaxone (200 mg/kg/day). Brain MRI revealed no significant abnormalities, and CSF analysis showed only a slight increase in the protein level. After completing the treatment course, he was discharged with no complication. In the current presentation, however, his symptoms were more severe and he had decreased level of consciousness. Therefore, considering his critical condition and severity of symptoms, the patient was admitted to PICU. Brain MRI revealed bilateral symmetrical relatively expansile, T2-hyperintense lesions and fluid-attenuated inversion recovery (FLAIR) hypersignal change involving both thalami and pons (Figure 2(b)). Unfortunately, the patient was expired two months later.

Figure 1: MRI images of case 1 at the (a) first and the (b) second admission.
Despite receiving immunosuppressive therapies such as methylprednisolone (2 mg/kg/day) and IVIG (2 g/kg/day) and while he was receiving appropriate care in PICU.

3. Discussion

For the first time in Iran, we reported three cases of ANE with mutations in the RANBP2 gene. ANE was first described in 1995 [1], since then several nonfamilial (sporadic) case reports of ANE have been published mostly in Eastern Asia. Neilson and colleagues in 2009 performed a genetic analysis of family members affected with ANE [5]. The authors found a recurrent missense mutation in the RANBP2 gene in family members diagnosed with ANE with an autosomal dominant pattern. Only 40% of the heterozygotes for RANBP2 mutation will manifest an episode of ANE. Thus, the penetrance was thought to be incomplete. This fact may explain the lack of symptoms in the mother of our first two cases.

RANBP2 gene, at a cellular level, is responsible for nucleocytoplasmic trafficking, protein biogenesis, the formation of the mitotic spindle, assembly of the nuclear envelope, and maturation during early mitotic progression [9]. RANBP2 gene mutation is mostly apparent by central nervous system (CNS) involvement. This is attributable to CNS-selective role of RANBP2, which may also underlie the pathogenesis of certain neuropathies [9]. However, the exact pathophysiologic mechanism of RANBP2 mutation and its association ANE remains to be clearly understood.

Similar to previous reports, the patients presented in this study had thalami, external capsules, midbrain, pons, and cerebellum involvements in neuroimaging. However, our third case showed these typical findings only at the second presentation which attributed to the delay in diagnosis.

Treatment of ANE requires critical care management. Methylprednisolone, IVIG, and other immunosuppressants have been used to decrease immune-mediated CNS cell injury in ANE. A previous research suggested that administration of corticosteroids within 24 hours after the onset of symptoms was associated with an improved outcome of children with ANE [10].

Based on previous findings from thirty familial ANE cases, 13% of them expired, 57% had neurological or other types of sequelae, and 30% had complete recovery [7]. Accordingly, poor prognosis of familial ANE highlights the fact that high suspicion and early diagnosis of ANE are critical.

4. Conclusion

Familial ANE is a rapidly progressive encephalopathy associated a RANBP2 gene mutation. Physicians must be vigilant to suspect this rare entity especially when it presents with nonspecific neurological symptoms such as the decreased level of consciousness and generalized tonic-colonic seizure. Early identification of typical CNS involvement in neuroradiological study is probably the key factor for the early diagnosis of ANE and improving the prognosis.
Data Availability

All available information regarding this study has been reported in the manuscript. Any information can be obtained from corresponding author (hessamikamran@gmail.com) based on a reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] M. Mizuguchi, J. Abe, K. Mikkaichi et al., “Acute necrotising encephalopathy of childhood: a new syndrome presenting with multifocal, symmetric brain lesions,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 58, no. 5, pp. 555–561, 1995.

[2] B. Tabarki, F. Thabet, S. Al Shafi, N. Al Adwani, M. Chehab, and S. Al Shahwan, “Acute necrotizing encephalopathy associated with enterovirus infection,” Brain and Development, vol. 35, no. 5, pp. 454–457, 2013.

[3] D. E. Neilson, “The interplay of infection and genetics in acute necrotizing encephalopathy,” Current Opinion in Pediatrics, vol. 22, no. 6, pp. 751–757, 2010.

[4] Y.-J. Lee, S.-K. Hwang, S. M. Lee, and S. Kwon, “Familial acute necrotizing encephalopathy with RANBP2 mutation: the first report in Northeast Asia,” Brain and Development, vol. 39, no. 7, pp. 625–628, 2017.

[5] D. E. Neilson, M. D. Adams, C. M. D. Orr et al., “Infection-Triggered Familial or Recurrent Cases of Acute Necrotizing Encephalopathy Caused by Mutations in a Component of the Nuclear Pore, RANBP2,” The American Journal of Human Genetics, vol. 84, no. 1, pp. 44–51, 2009.

[6] N.-R. Loh and D. B. Appleton, “Untreated recurrent acute necrotising encephalopathy associated with RANBP2 mutation, and normal outcome in a Caucasian boy,” European Journal of Pediatrics, vol. 169, no. 10, pp. 1299–1302, 2010.

[7] R. R. Singh, S. Sedani, M. Lim, E. Wassmer, and M. Absoud, “RANBP2 mutation and acute necrotizing encephalopathy: 2 cases and a literature review of the expanding clinico-radiological phenotype,” European Journal of Paediatric Neurology, vol. 19, no. 2, pp. 106–113, 2015.

[8] E. J. Marco, J. E. Anderson, D. E. Neilson, and J. B. Strober, “Acute necrotizing encephalopathy in 3 brothers,” Pediatrics, vol. 125, no. 3, pp. e693–e698, 2010.

[9] A. Aslanukov, R. Bhowmick, M. Guruju et al., “RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolism,” PLoS Genetics, vol. 2, no. 10, article e177, 2006.

[10] A. Okumura, M. Mizuguchi, H. Kidokoro et al., “Outcome of acute necrotizing encephalopathy in relation to treatment with corticosteroids and gammaglobulin,” Brain and Development, vol. 31, no. 3, pp. 221–227, 2009.